Silencing KIF20A increases the sensitivity of cancer cells to oxaliplatin and suppresses NUAK1, thereby upregulating the expression of PP1β, which subsequently decreases the phosphorylation of downstream GSK3β to suppress the activation of Nrf2 and the expression of GPX4, abolishing oxaliplatin resistance in these cells.163. The gene discussed is NFE2L2; the disease is cancer.